Rectovaginal fistula in Crohn's disease treatment: a low long-term success rate and a high definitive stoma risk after a conservative surgical approach.
Crohn’s disease
Rectovaginal fistula
Surgery
Journal
Techniques in coloproctology
ISSN: 1128-045X
Titre abrégé: Tech Coloproctol
Pays: Italy
ID NLM: 9613614
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
received:
30
08
2020
accepted:
11
08
2021
pubmed:
27
8
2021
medline:
22
9
2021
entrez:
26
8
2021
Statut:
ppublish
Résumé
Management of rectovaginal fistula (RVF) in Crohn's disease (CD) is challenging. Available studies are heterogeneous and retrospective, with short-term follow-up. The aim of this study was to assess the overall long-term medico-surgical treatment results in women with RVF due to CD. A retrospective study was conducted on consecutive patients operated on for RVF in CD from September 1996 to November 2019 at a tertiary teaching hospital. All surgeries were classified as preliminary, closure, or salvage procedures. Primary outcome was fistula remission defined as the combination of fistula closure and no stoma, at least 6 months since last procedure. Thirty-two patients (median age 34 [range 21-55] years), with a median follow-up of 11.3 years (0-23.7) after first surgery, were included. Altogether, 138 procedures were performed; 36 (26%) preliminary, 80 (58%) closure, and 13 (9%) salvage procedures. RVF remission was obtained in 7/32 patients (22%). At the end of follow-up, a stoma was present in 13/32 patients (41%). The percentage of time on biologics was 86% for patients in remission, versus 36% for the others (p = 0.0057). After univariate analysis, only anti-TNF-α was significantly related to successful closure techniques (p = 0.007). The RVF remission rate in CD was low in the long term. However, patients underwent a succession of interventions, and the stoma rate was high. Combination of biologics with surgical management was crucial.
Sections du résumé
BACKGROUND
BACKGROUND
Management of rectovaginal fistula (RVF) in Crohn's disease (CD) is challenging. Available studies are heterogeneous and retrospective, with short-term follow-up. The aim of this study was to assess the overall long-term medico-surgical treatment results in women with RVF due to CD.
METHODS
METHODS
A retrospective study was conducted on consecutive patients operated on for RVF in CD from September 1996 to November 2019 at a tertiary teaching hospital. All surgeries were classified as preliminary, closure, or salvage procedures. Primary outcome was fistula remission defined as the combination of fistula closure and no stoma, at least 6 months since last procedure.
RESULTS
RESULTS
Thirty-two patients (median age 34 [range 21-55] years), with a median follow-up of 11.3 years (0-23.7) after first surgery, were included. Altogether, 138 procedures were performed; 36 (26%) preliminary, 80 (58%) closure, and 13 (9%) salvage procedures. RVF remission was obtained in 7/32 patients (22%). At the end of follow-up, a stoma was present in 13/32 patients (41%). The percentage of time on biologics was 86% for patients in remission, versus 36% for the others (p = 0.0057). After univariate analysis, only anti-TNF-α was significantly related to successful closure techniques (p = 0.007).
CONCLUSIONS
CONCLUSIONS
The RVF remission rate in CD was low in the long term. However, patients underwent a succession of interventions, and the stoma rate was high. Combination of biologics with surgical management was crucial.
Identifiants
pubmed: 34436729
doi: 10.1007/s10151-021-02506-8
pii: 10.1007/s10151-021-02506-8
doi:
Substances chimiques
Tumor Necrosis Factor Inhibitors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1143-1149Informations de copyright
© 2021. Springer Nature Switzerland AG.
Références
Schwartz DA, Loftus EV, Tremaine WJ et al (2002) The natural history of fistulizing Crohn’s disease in Olmsted County, Minnesota. Gastroenterology 122:875–880
doi: 10.1053/gast.2002.32362
Sandborn WJ, Fazio VW, Feagan BG, Hanauer SB, Committee AGACP (2003) AGA technical review on perianal Crohn’s disease. Gastroenterology 125:1508–1530
doi: 10.1016/j.gastro.2003.08.025
Parsi MA, Lashner BA, Achkar J-P, Connor JT, Brzezinski A (2004) Type of fistula determines response to infliximab in patients with fistulous Crohn’s disease. Am J Gastroenterol 99:445–449
doi: 10.1111/j.1572-0241.2004.04083.x
El-Gazzaz G, Hull T, Mignanelli E, Hammel J, Gurland B, Zutshi M (2010) Analysis of function and predictors of failure in women undergoing repair of Crohn’s related rectovaginal fistula. J Gastrointest Surg 14:824–829
doi: 10.1007/s11605-010-1167-1
Leroy A, Azaïs H, Giraudet G, Cosson M (2017) Quality of life and symptoms before and after surgical treatment of rectovaginal fistula. Prog Urol 27:229–237
doi: 10.1016/j.purol.2016.12.001
Bouchard D, Abramowitz L, Bouguen G et al (2017) Anoperineal lesions in Crohn’s disease: French recommendations for clinical practice. Tech Coloproctol 21:683–691
doi: 10.1007/s10151-017-1684-y
Ruffolo C, Penninckx F, Assche GV et al (2009) Outcome of surgery for rectovaginal fistula due to Crohn’s disease. Br J Surg 96:1190–1195
doi: 10.1002/bjs.6661
Corte H, Maggiori L, Treton X, Lefevre JH, Ferron M, Panis Y (2015) Rectovaginal fistula: what is the optimal strategy?: An analysis of 79 patients undergoing 286 procedures. Ann Surg 262:855–860 (discussion 860–861)
doi: 10.1097/SLA.0000000000001461
Gaertner WB, Madoff RD, Spencer MP, Mellgren A, Goldberg SM, Lowry AC (2011) Results of combined medical and surgical treatment of recto-vaginal fistula in Crohn’s disease. Colorectal Dis 13:678–683
doi: 10.1111/j.1463-1318.2010.02234.x
Pinto RA, Peterson TV, Shawki S, Davila GW, Wexner SD (2010) Are there predictors of outcome following rectovaginal fistula repair? Dis Colon Rectum 53:1240–1247
doi: 10.1007/DCR.0b013e3181e536cb
Löffler T, Welsch T, Mühl S, Hinz U, Schmidt J, Kienle P (2009) Long-term success rate after surgical treatment of anorectal and rectovaginal fistulas in Crohn’s disease. Int J Colorectal Dis 24:521–526
doi: 10.1007/s00384-009-0638-x
Satsangi J, Silverberg MS, Vermeire S, Colombel J (2006) The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 55:749–753
doi: 10.1136/gut.2005.082909
Sands BE, Anderson FH, Bernstein CN et al (2004) Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med 350:876–885
doi: 10.1056/NEJMoa030815
Colombel J-F, Schwartz DA, Sandborn WJ et al (2009) Adalimumab for the treatment of fistulas in patients with Crohn’s disease. Gut 58:940–948
doi: 10.1136/gut.2008.159251
Present DH, Rutgeerts P, Targan S et al (1999) Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med 340:1398–1405
doi: 10.1056/NEJM199905063401804
Irvine EJ (1995) Usual therapy improves perianal Crohn’s disease as measured by a new disease activity index. McMaster IBD Study Group. J Clin Gastroenterol 20:27–32
doi: 10.1097/00004836-199501000-00008
Vaizey C, Carapeti E, Cahill J, Kamm M (1999) Prospective comparison of faecal incontinence grading systems. Gut 44:77–80
doi: 10.1136/gut.44.1.77
Andreani SM, Dang HH, Grondona P, Khan AZ, Edwards DP (2007) Rectovaginal fistula in Crohn’s disease. Dis Colon Rectum 50:2215–2222
doi: 10.1007/s10350-007-9057-7
Sands BE, Blank MA, Patel K, van Deventer SJ, ACCENT II Study (2004) Long-term treatment of rectovaginal fistulas in Crohn’s disease: response to infliximab in the ACCENT II Study. Clin Gastroenterol Hepatol 2:912–920
doi: 10.1016/S1542-3565(04)00414-8
Hyder SA, Travis SPL, Jewell DP, McC Mortensen NJ, George BD (2006) Fistulating anal Crohn’s disease: results of combined surgical and infliximab treatment. Dis Colon Rectum 49:1837–1841
doi: 10.1007/s10350-006-0656-5
Ryoo S-B, Oh H-K, Ha H-K et al (2019) Outcomes of surgical treatments for rectovaginal fistula and prognostic factors for successful closure: a single-center tertiary hospital experiences. Ann Surg Treat Res 97:149–156
doi: 10.4174/astr.2019.97.3.149
Grimaud J-C, Munoz-Bongrand N, Siproudhis L et al (2010) Fibrin glue is effective healing perianal fistulas in patients with Crohn’s disease. Gastroenterology 138:2275–2281
doi: 10.1053/j.gastro.2010.02.013
Ruffolo C, Scarpa M, Bassi N, Angriman I (2010) A systematic review on advancement flaps for rectovaginal fistula in Crohn’s disease: transrectal vs transvaginal approach. Colorectal Dis 12:1183–1191
doi: 10.1111/j.1463-1318.2009.02029.x
Kelly ME, Heneghan HM, McDermott FD et al (2014) The role of loose seton in the management of anal fistula: a multicenter study of 200 patients. Tech Coloproctol 18:915–919
doi: 10.1007/s10151-014-1186-0
Faucheron JL, Saint-Marc O, Guibert L, Parc R (1996) Long-term seton drainage for high anal fistulas in Crohn’s disease—a sphincter-saving operation? Dis Colon Rectum 39:208–211
doi: 10.1007/BF02068077
Thornton M, Solomon MJ (2005) Long-term indwelling seton for complex anal fistulas in Crohn’s disease. Dis Colon Rectum 48:459–463
doi: 10.1007/s10350-004-0830-6
Marchesa P, Hull TL, Fazio VW (1998) Advancement sleeve flaps for treatment of severe perianal Crohn’s disease. Br J Surg 85:1695–1698
doi: 10.1046/j.1365-2168.1998.00959.x
Singh S, Ding NS, Mathis KL et al (2015) Systematic review and meta-analysis: faecal diversion for management of perianal Crohn’s disease. Aliment Pharmacol Ther 42:783–792
doi: 10.1111/apt.13356
Hain E, Maggiori L, Orville M, Tréton X, Bouhnik Y, Panis Y (2019) Diverting stoma for refractory ano-perineal Crohn’s disease: Is it really useful in the Anti-TNF era? A multivariate analysis in 74 consecutive patients. J Crohns Colitis 13:572–577
doi: 10.1093/ecco-jcc/jjy195
Mueller MH, Geis M, Glatzle J et al (2007) Risk of fecal diversion in complicated perianal Crohn’s disease. J Gastrointest Surg 11:529–537
doi: 10.1007/s11605-006-0029-3
Sahnan K, Tozer PJ, Adegbola SO et al (2019) Developing a core outcome set for fistulising perianal Crohn’s disease. Gut 68:226–238
doi: 10.1136/gutjnl-2017-315503
Yarur AJ, Kanagala V, Stein DJ et al (2017) Higher infliximab trough levels are associated with perianal fistula healing in patients with Crohn’s disease. Aliment Pharmacol Ther 45:933–940
doi: 10.1111/apt.13970